Literature DB >> 6819097

Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

N Hartman, P J Basseches, G Powis.   

Abstract

The effect of pretreatment with cyclophosphamide 180 mg/kg upon the short-term disposition of adriamycin in anesthetized rat 4 days later was studied. There was a significant decrease in plasma adriamycin clearance, from 125 to 48 ml/min/kg, and a significant decrease in the apparent volume of the peripheral compartment of adriamycin distribution, from 51.7 to 25.6 l/kg, in cyclophosphamide-pretreated as against control rats. Biliary excretion of adriamycin over 2.5 h was increased significantly by 114% in cyclophosphamide-pretreated rats and there was a small but nonsignificant increase in biliary adriamycinol excretion and a decrease in excretion of adriamycin aglycones. Cyclophosphamide pretreatment was associated with an 83% increase in bile flow. Cyclophosphamide pretreatment had no significant effect upon the utilization of adriamycin or upon the formation of adriamycin metabolites by rat isolated hepatocytes. The results suggest that NADPH-cytochrome P-450 reductase, which is decreased 40% by cyclophosphamide pretreatment, is not rate-limiting in elimination of adriamycin. Biliary excretion of adriamycin is increased when plasma adriamycin clearance is decreased, suggesting that cyclophosphamide pretreatment affects a pathway besides biliary excretion that is responsible for the short-term removal of adriamycin from plasma.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6819097     DOI: 10.1007/bf00257229

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

1.  Adriamycin metabolism in man. Evidence from urinary metabolites.

Authors:  S Takanashi; N R Bachur
Journal:  Drug Metab Dispos       Date:  1976 Jan-Feb       Impact factor: 3.922

2.  Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.

Authors:  F M Muggia; M Perloff; G A Chia; L J Reed; G C Escher
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

3.  Structure-antitumor activity relationships among quinone derivatives.

Authors:  J S Driscoll; G F Hazard; H B Wood; A Goldin
Journal:  Cancer Chemother Rep 2       Date:  1974-04

4.  NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals.

Authors:  N R Bachur; S L Gordon; M V Gee; H Kon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

5.  Studies of the effects of cyclophosphamide, vincristine, and prednisone on some hepatic oxidations and conjugations.

Authors:  H L Gurtoo; T Gessner; P Culliton
Journal:  Cancer Treat Rep       Date:  1976-09

6.  Anthracycline antibiotic pharmacology and metabolism.

Authors:  N R Bachur
Journal:  Cancer Treat Rep       Date:  1979-05

7.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.

Authors:  S Eksborg; H Ehrsson; I Andersson
Journal:  J Chromatogr       Date:  1979-12-01

8.  Determination of adriamycin (doxorubicin) and related fluorescent compounds in rat lymph and gall by high-performance liquid chromatography.

Authors:  S Shinozawa; T Oda
Journal:  J Chromatogr       Date:  1981-08-07

9.  Iron-EDTA stimulated reduction of indicine N-oxide by the hepatic microsomal fraction, isolated hepatocytes, and the intact rat.

Authors:  G Powis; B A Svingen; C Degraw
Journal:  Biochem Pharmacol       Date:  1982-02-01       Impact factor: 5.858

10.  Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography.

Authors:  P A Andrews; D E Brenner; F T Chou; H Kubo; N R Bachur
Journal:  Drug Metab Dispos       Date:  1980 May-Jun       Impact factor: 3.922

View more
  4 in total

Review 1.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

2.  Variability in the pharmacokinetics of epirubicin: a population analysis.

Authors:  J R Wade; A W Kelman; D J Kerr; J Robert; B Whiting
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Hepatic extraction, metabolism and biliary excretion of doxorubicin in the isolated perfused rat liver.

Authors:  F Ballet; P Vrignaud; J Robert; C Rey; R Poupon
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Hepatic metabolism of doxorubicin in mice and rats.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.